Considerations include: Lower initial dosing where appropriate Close monitoring for gastrointestinal intolerance Assessment of comorbidities and polypharmacy risks 15.2 Administration to Pregnant Women Human data remain limited
doi: 10.3389/fendo.2025.1483199 Received 19 August 2024 Accepted 10 January 2025 Published 17 February 2025 Volume 16 - 2025 Edited by Brenda Kohn, New York University, United States Reviewed by Ekaterina Koledova, Merck, Germany Torben Laursen, Aarhus University Hospital, Denmark Updates Copyright 2025 Levshtein, Sharkia, Shimshi-Barash, Almagor, Albertsson-Wikland, Hochberg, Pillar and German
Use needles of shorter length (4 mm or the shortest available) and smaller diameter (highest gauge number), and the tip with the lowest penetration force to minimize pain
Again, coverage is only likely when the GLP-1 drug is prescribed for an FDA-approved use
Foundational tendon-bone work includes Krivic et al
Prior coverage of Luvo Health's broader program lineup, brand-wide reviews, and complaint research goes deeper on that company-wide picture